Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Free Report)’s stock price shot up 2.7% on Monday . The stock traded as high as $3.30 and last traded at $2.69. 578,951 shares were traded during mid-day trading, an increase of 519% from the average session volume of 93,476 shares. The stock had previously closed at $2.62.
Salarius Pharmaceuticals Trading Down 7.8 %
The company has a market cap of $3.57 million, a price-to-earnings ratio of -0.30 and a beta of 0.83. The stock’s 50-day moving average is $1.69 and its 200-day moving average is $1.78.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
Featured Articles
- Five stocks we like better than Salarius Pharmaceuticals
- Conference Calls and Individual Investors
- Rivian: Weathering the Storm, Poised for Growth?
- The 3 Best Blue-Chip Stocks to Buy Now
- Avient Stock: Manufacturing Play With Double-Digit Upside
- 3 REITs to Buy and Hold for the Long Term
- Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
